SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Transcept Pharmaceuticals, Inc. Completes Patient Enrollment in Phase 2 Clinical Trial of TO-2061 Added as Adjunctive Therapy for Obsessive Compulsive Disorder